Innovations in drug research: inhibitors of thromboxane and leukotrienes.
Ford-Hutchinson
A W
AW
Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, Quebec, Canada.
D058927:5-Lipoxygenase-Activating Proteins; D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D020024:Leukotriene Antagonists; D008565:Membrane Proteins / Q000378:metabolism; D011422:Propionates / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D011971:Receptors, Immunologic / Q000187:drug effects; D018077:Receptors, Leukotriene; D012106:Research; D013931:Thromboxanes / Q000037:antagonists & inhibitors*; D002722:Chlorobenzenes
D058927:5-Lipoxygenase-Activating Proteins; D002352:Carrier Proteins; D007211:Indoles; D020024:Leukotriene Antagonists; D008565:Membrane Proteins; D011422:Propionates; D011804:Quinolines; D011971:Receptors, Immunologic; D018077:Receptors, Leukotriene; D013931:Thromboxanes; C548592:ALOX5AP protein, human; C060893:MK-886; D002722:Chlorobenzenes; C059141:verlukast